Hunan Warrant PharmaceuticalLtd Past Earnings Performance
Past criteria checks 4/6
Hunan Warrant PharmaceuticalLtd has been growing earnings at an average annual rate of 14%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 11.9% per year. Hunan Warrant PharmaceuticalLtd's return on equity is 11%, and it has net margins of 15.3%.
Key information
14.0%
Earnings growth rate
5.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 11.9% |
| Return on equity | 11.0% |
| Net Margin | 15.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Hunan Warrant PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,448 | 222 | 616 | 104 |
| 31 Dec 23 | 1,433 | 211 | 597 | 103 |
| 30 Sep 23 | 1,421 | 217 | 580 | 106 |
| 30 Jun 23 | 1,421 | 211 | 593 | 109 |
| 31 Mar 23 | 1,358 | 198 | 595 | 103 |
| 31 Dec 22 | 1,293 | 183 | 598 | 89 |
| 30 Sep 22 | 1,267 | 182 | 605 | 82 |
| 30 Jun 22 | 1,219 | 175 | 609 | 71 |
| 31 Mar 22 | 1,201 | 161 | 607 | 68 |
| 31 Dec 21 | 1,147 | 161 | 587 | 70 |
| 30 Sep 21 | 1,120 | 158 | 581 | 59 |
| 30 Jun 21 | 1,083 | 157 | 546 | 64 |
| 31 Mar 21 | 1,005 | 154 | 495 | 70 |
| 31 Dec 20 | 951 | 145 | 463 | 64 |
| 31 Dec 19 | 825 | 116 | 401 | 45 |
| 31 Dec 18 | 613 | 88 | 292 | 26 |
| 31 Dec 15 | 256 | 19 | 86 | 0 |
| 31 Dec 14 | 247 | 28 | 81 | 0 |
| 31 Dec 13 | 194 | 21 | 69 | 0 |
Quality Earnings: 688799 has high quality earnings.
Growing Profit Margin: 688799's current net profit margins (15.3%) are higher than last year (14.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688799's earnings have grown by 14% per year over the past 5 years.
Accelerating Growth: 688799's earnings growth over the past year (12.2%) is below its 5-year average (14% per year).
Earnings vs Industry: 688799 earnings growth over the past year (12.2%) exceeded the Pharmaceuticals industry -1.1%.
Return on Equity
High ROE: 688799's Return on Equity (11%) is considered low.